ArQule, Inc. (NASDAQ:ARQL)

CAPS Rating: 4 out of 5

A clinical-stage biotechnology company, engaged in the research and development of cancer therapeutics. Its mission is to research, develop and commercialize targeted cancer drugs with reduced toxicities compared to conventional cancer chemotherapeutics.

Results 1 - 20 of 24 : 1 2 Next »

Recs

0
Member Avatar OklaBoston (63.63) Submitted: 3/9/2015 7:17:09 PM : Outperform Start Price: $2.47 ARQL Score: -9.43

Valuations don't look very good but the technicals SCREAM breakout.

Looks like years of insider open market buying is about to be rewarded.

Cover shorts in this, SOONEST!

Recs

0
Member Avatar chall77 (< 20) Submitted: 2/1/2014 6:40:50 PM : Outperform Start Price: $2.30 ARQL Score: -18.95

I understand they have a promising liver drug on the way that is supposed to be a strong performer for the company

Recs

0
Member Avatar chris293 (91.60) Submitted: 1/9/2014 5:20:00 PM : Outperform Start Price: $2.25 ARQL Score: -12.96

I really don't know, if this company makes it, maybe is has hit bottom and the only is up. 5 Stars by the 'Motley Fool' must mean something, why? Who or where is any good news? Cancer research can be a big scam but I would hope this company can make it with some cures.

Recs

0
Member Avatar TerryHoodSr (79.91) Submitted: 8/6/2013 10:20:17 PM : Outperform Start Price: $2.38 ARQL Score: -31.15

spec

Recs

2
Member Avatar MrOneHundred (30.13) Submitted: 2/24/2013 3:56:22 AM : Outperform Start Price: $2.41 ARQL Score: -42.78

I'm having a hard time reconciling a decent reason not to risk this stock with real money. In my opinion, at $2/share the company is poised to repeat miraculous gains in a relatively near future. Only twice in the past eleven years has this stock been this low. Its price has climbed up to as high as $10 in times past! With the company's current pipeline, a plausible economic crisis (something this sector can be relatively immune to and could therefore draw investors), and add in the fact that ArQule is presenting at the RBC Capital Markets Global Healthcare Conference coming this Tuesday... it seems likely that something positive, no matter how minute, will likely send this stock up quick. Dilution, or other bad things could happen, but I'm having a difficult time seeing it happen with this company. The fundamentals on this stock are shaky, though. This is not without risk.

Recs

0
Member Avatar scottbiddle64 (< 20) Submitted: 1/14/2013 11:58:24 PM : Underperform Start Price: $2.50 ARQL Score: +52.04

Failure on clinical trials

Recs

0
Member Avatar BicaChica (80.51) Submitted: 4/5/2010 3:51:38 PM : Underperform Start Price: $6.29 ARQL Score: +137.00

tenmiles

Recs

0
Member Avatar quinpeung (41.19) Submitted: 3/31/2010 1:19:25 PM : Outperform Start Price: $6.45 ARQL Score: -142.25

Mr. negative here, uncharacteristically giving a green thumb to a biotech stock. But if the phase III results are solid for the combination of ARQ 197 and Tarceva, and given Astellas' current pursuit of OSIP (markets Tarceva), the future looks bright for ARQL.

Recs

0
Member Avatar wakoma (< 20) Submitted: 9/29/2008 7:46:43 AM : Outperform Start Price: $3.15 ARQL Score: -107.45

Bought based on feedback from a couple of friends in the oncology industry. Small position. yrs away from knowing the outcome. Some smart money likes what they see. Who knows. Pretty much dead money for the near term

Recs

0
Member Avatar Dapperatom (< 20) Submitted: 5/14/2008 1:54:31 PM : Outperform Start Price: $4.23 ARQL Score: -98.51

I like the below $10 price and its potential for a good return.

Recs

0
Member Avatar spicebyr (84.59) Submitted: 4/27/2008 9:42:21 AM : Outperform Start Price: $3.84 ARQL Score: -95.53

This issue has too many LARGE investment banks/investors putting $$$ into it. Currently (late April 2008) it has been beaten to a point where an entry at this level will "probably" provide 100% ROI. Everyone is responsible for their own due diligence. This is one that has GREAT potential!!!

Recs

0
Member Avatar Fundzrlow (< 20) Submitted: 4/24/2008 11:40:43 AM : Outperform Start Price: $3.85 ARQL Score: -97.46

I think this an upcoming stock, although it fluctuates it is a strong stock.

Recs

0
Member Avatar zacprince (< 20) Submitted: 9/24/2007 8:41:15 PM : Outperform Start Price: $7.50 ARQL Score: -114.36

best wall street player likes it, there probably smarter than me, so im going for it.

Recs

0
Member Avatar myersfield (< 20) Submitted: 8/27/2007 2:35:38 PM : Outperform Start Price: $7.86 ARQL Score: -119.49

2 hottest new best in class cancer drug programs in phase 2: c-met and E2F1 checkpoint activators should lead to good deals, broad application, high efficiency, negligible side effects.

Recs

0
Member Avatar mcmartinson (96.34) Submitted: 8/1/2007 3:39:16 PM : Outperform Start Price: $5.53 ARQL Score: -110.25

Safety profile of their C-Met inhibitor should win out over the Exelixis inhibitor in the clinic.

Recs

0
Member Avatar barrettfodder (68.54) Submitted: 6/21/2007 9:59:17 AM : Outperform Start Price: $7.62 ARQL Score: -115.83

If the next phase of clinical trials goes well. This company will be set for the remainder of its life. Worth a look

Recs

0
Member Avatar aclowe01 (27.67) Submitted: 6/14/2007 11:23:18 AM : Outperform Start Price: $7.84 ARQL Score: -115.31

The Cancer Survival Protein modulation program
is a home run for this small growing company.

Recs

0
Member Avatar 2tal (< 20) Submitted: 4/10/2007 1:50:12 PM : Outperform Start Price: $8.40 ARQL Score: -125.05

A biotech that is starting to hit its stride. The stock is starting to move regularly and in the right direction.

Recs

0
Member Avatar kostian (81.35) Submitted: 3/26/2007 11:11:23 PM : Outperform Start Price: $7.39 ARQL Score: -123.05

just gonna try getting in at this hoping for something good
at $7.30
might be a short or might go long.

Recs

2
Member Avatar NetscribeHealthC (76.21) Submitted: 3/12/2007 6:45:39 AM : Outperform Start Price: $6.59 ARQL Score: -122.93

ArQule is developing a portfolio of proprietary small molecule drugs to treat cancer. The company’s technology platform includes the Activated Checkpoint Therapy (ACT) program, which seeks to harness the cell's natural defense mechanism against genetic (DNA) damage. While ArQule was previously a leading chemistry services company, since mid-2006, it has repositioned itself as an oncology company focused on developing internally discovered drug candidates.

The company's cancer product, ARQ 501, currently in a Phase II trial, which is based on its ACT platform, plans to announce Phase II results from ARQ 501 around mid-2007. The company's second clinical-stage product, ARQ 197, completing Phase I clinical trial, is designed to trigger death in cancer cells. It expects to initiate Phase II trials in second quarter of 2007. ArQule also has a number of pre-clinical programs based on product candidates directed towards molecular targets.

The company’s revenue, which is currently derived from research and development funding from its alliance with Hoffmann-La Roche, Inc. (Roche), remained flat at $6.6 million, for the year ended December 2006. Revenue from its chemistry services business ceased in the second quarter of 2006 as a result of its strategic decision to exit this business and the subsequent decision by Pfizer to terminate its agreement with effect from May 2006.

ArQule looks like an attractive investment proposition on the premise that ARQ 501 is completing a broad Phase II development program, its partnership with Roche for ARQ 501 which is worth up to $276 million in research funding and clinical development milestones and a series of pre-clinical oncology programs utilizing the ACT platform. Compared to fiscal 2006, the company’s management expects to generate revenues in excess of 8% during fiscal 2007.

Results 1 - 20 of 24 : 1 2 Next »

Featured Broker Partners


Advertisement